Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands
Autor: | Rob ter Heine, Marco van Vulpen, Anko Kooistra, Geert W.J. Frederix, Anke M. Hövels, Haiko J. Bloemendal, Joost W Geenen, John M. H. de Klerk |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
Male medicine.medical_specialty Antineoplastic Agents Hormonal Total cost Cost-Benefit Analysis Brachytherapy Bone Neoplasms 03 medical and health sciences Prostate cancer 0302 clinical medicine Quality of life Cost of Illness Internal medicine medicine Cost of illness Humans Intensive care medicine health care economics and organizations Aged Netherlands Retrospective Studies Aged 80 and over Prostatectomy business.industry 030503 health policy & services Health Policy Treatment options Prostatic Neoplasms Length of Stay Middle Aged Prostate-Specific Antigen medicine.disease lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] 030220 oncology & carcinogenesis Quality of Life Resource use 0305 other medical science business |
Zdroj: | Journal of Comparative Effectiveness Research, 6, 7, pp. 575-581 Journal of Comparative Effectiveness Research, 6, 575-581 |
ISSN: | 2042-6305 |
Popis: | Aim: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs). Methods: We performed a bottom-up cost of illness study in The Netherlands. Results: A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of €2039–9346, depending on care. These SREs had median costs of €200–1912. Conclusion: Our data provide a basis to investigate the cost–effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction. |
Databáze: | OpenAIRE |
Externí odkaz: |